| |
 |
GENEMAX
CORPORATION (OTCBB: GMXX) (FRANKFURT AND BERLIN EXCHANGES:
GX1) |
 |
Dear Reader,
We recently profiled GeneMax Corp. (OTCBB: GMXX)
- a company that continues to draw the attention of Wall Street
and the medical community. GMXX is developing a therapeutic
vaccine for the treatment of cancer based on its proprietary TAP
(Transporters Associated with Antigen Processing) technology that
restores the ability of the immune system to recognize and attack
cancerous cells. GMXX is focused on commercializing this
technology as the basis for developing effective vaccines for
the treatment of cancer. Click
here to read our full profile (8/7/03)
The KonLin Letter
Recommends GMXX (Sept. 03)
| GMXX
was featured by SmallCap stock veteran Konrad Kuhn in the
September issue of The KonLin Letter, an icon
in the low-priced stock sector for as long as I can remember.
KonLin placed an Ultimate Target Price of $9 -$10
on GMXX. Here are some brief excerpts from
the writeup:
"The second leading
cause of mortality in the U.S. is cancer, attributed to
500,000 deaths annually. With the aging population,
it is just a matter of time before cancer will become
the leading cause of death."
KonLin originally
recommended GMXX in September '02. "
...investors and traders realized 300% gains, mainly due
to the enourmous short covering."
"A successful trial
in an animal model of small cell lung cancer, with a survival
rate up to 70%, has established proof of concept.
Further studies using melanoma (skin cancer) confirms
the results from the lung cancer studies. We advise
reentering the stock for a 1st target of 5 - 6 since its
TAP cancer vaccine is now ready for its clinical trial
program.
Since a defect in
the TAP protein is a fundamental mechanism by which cancer
avoids detection by the immune system, the GMXX TAP cancer
vaccine offers a therapeutic approach to any type of cancer
in which this system is not functioning. TAP cancer
vaccines are expected, therefore, to be an efficetive
therapy for a large portion of more common cancers.
Ultimate target is 9 - 10."
The KonLin Letter
selects 5 stocks each month (and monitors dozens more)
while providing a broad range of technical information
with buy/sell and market timing advice. KonLin has
consistantly been one of the leading publications in the
SmallCap stock sector and has been rated as one of the
best performing market letters in the nation.
For more information visit www.KonLin.com.
|
GeneMax has Breaking News
today that you won't want to miss.
Read On!
|
**Breaking
News**FROM GENEMAX |
|
Press Release
Source: GeneMax
Corp.
Tuesday September
9, 11:55 am ET
GeneMax Corp.
Announces Agreement with Molecular Medicine BioServices, Inc.
for the Production of TAP Cancer Vaccine
BLAINE, Wash., Sept. 9 /PRNewswire-FirstCall/--GeneMax
Corp. (OTC Bulletin Board:GMXX; Frankfurt and Berlin: GX1) today
announced an amended contractual agreement with Molecular Medicine
BioServices, Inc. of San Diego, California for the production
of its clinical vector for delivery of the TAP genes (Transporters
Associated with Antigen Processing) used in GeneMax's lead product,
an immunotherapy aimed to treat a wide variety of carcinomas that
include lung cancers, liver cancers, kidney cancers, head and
neck cancers, breast cancers, melanomas, prostate cancers, colorectal
cancers, and cervical cancers. The new production contract incorporates
the use of a proprietary adenovirus-based vectoral technology
from Crucell, which was licensed and announced by GeneMax in August
2003.
The new contract is based on
production of sufficient vaccine to conduct the balance of pre-clinical
work as well as Phase I/IIa clinical trials. The contract defines
that the product is to be tested by an independent laboratory.
Toxicology tests are planned on the product before filing the
IND (Investigational New Drug application). Management expects
that Phase I/IIa Clinical trials can begin in Q2 of next year
subject to adequate funding. Based on GeneMax's internal development
program, projects within the new contract include:
- Vector Construction and
Cloning
- Production of an Adenoviral
Master Viral Bank,
- Pilot Production under cGMP
(Good Manufacturing Practice standards as set forth by US FDA
regulation US 21 CFR Parts 210 and 211 for pilot scale facilities
and 21 CFR Part 600 applicable to biologics) and,
- cGMP Clinical Vector Production
Lot.
Ronald L. Handford, President &
CEO of GeneMax, said, "We are now in a position to clearly outline
the final steps to advance GeneMax's TAP cancer immunotherapy into
clinical trials. We have had an excellent track record of meeting
or surpassing our corporate milestones during pre-clinical development
stages. Since going public one year ago, GeneMax has raised some
US$3 million; in turn the Company has expanded the intellectual
property position on the TAP technology. Genemax has also tested
several delivery vectors to define maximum efficacy for use in the
TAP immunotherapy, and has negotiated and licensed the preferred
vector from Crucell. Furthermore, Genemax has also attracted some
of the world's top scientists and medical professionals to the Board
and Scientific Advisory Board. Lastly the Company has now put a
production contract in place with Molecular Medicine for the Company's
clinical trials program. In the coming year, GeneMax plans to expand
its operations in the areas of clinical development and business
development. This added expertise will ensure efficient progress
towards taking the TAP immunotherapy into the clinic. GeneMax also
expects to expand relationships with other companies that will aid
in the development of our TAP technology pipeline."
Based on cancer incidence data
collected for the year 2000 from a Lyon, IARCPress document of
2001, the Company's TAP cancer technology, if successful, may
form a relevant immunotherapy for 60%-70% of all new incidences
of cancer in the US, Japan, and the four major European markets.
The competitive advantages include: efficacy against secondary
cancerous growths elsewhere in the body, no restrictions on the
patient's HLA type, no restrictions regarding the genetics of
the tumors, and non-toxicity to normal cells. The technology is
complementary and synergistic with all other immunotherapies dependent
on cytotoxic T cell killing and also has the potential to enable
a variety of tumor antigen vaccines.
GeneMax Lead Product: "TAP (Transporters
Associated With Antigen Processing)" --
An Immunotherapy for Many Forms
of Cancer. The global market for effective cancer treatments is
large. Immunotherapies represent potential treatments for metastatic
cancer, a substantial unmet need in the area of oncology. GeneMax's
lead product is a therapeutic that enables a body's immune system
to recognize the cancer cells as "foreign", and kill them. The
technology is aimed at a group of cancers that include lung cancer,
liver cancer, kidney cancer, head and neck cancer, breast cancer,
melanoma, prostate cancer, colorectal cancer, and cervical cancer.
These cancers are characterized by defects in the cellular, antigen
presentation pathway, which results in the cancers becoming invisible
to the immune system. This allows the cancers to continue to proliferate
and eventually spread. GeneMax's lead technology increases the
activity of the antigen presentation pathway thus providing sufficient
information to the immune system to cause rejection and elimination
of tumors from the body. The proof of principle was established
in mice bearing metastatic small cell lung cancer tumors. This
study was published in Nature Biotechnology (Vol. 18, pp 515-520,
May 2000) Development Stage: Pre-clinical, preparing for Phase
I/IIa Clinical Trials.
About GeneMax Corp.:
GeneMax Corp. is a biotechnology company specializing in the discovery
and development of immunotherapeutics aimed at the treatment and
eradication of cancer, and therapies
for infectious diseases, autoimmune disorders and transplant tissue
rejection.
SAFE HARBOR STATEMENT
THIS NEWS RELEASE MAY INCLUDE
FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF
THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION
21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934,
AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING
ADDITIONAL PROJECT INTERESTS, THE COMPANY'S ANALYSIS OF OPPORTUNITIES
IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS
AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE
"SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES
WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE
IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN."
Source: GeneMax Corp.
GeneMax Corporation is a product-focused biotechnology
company that is applying discoveries in cellular immunology and
cancer biology to the development of proprietary therapeutics
for cancer and immunological diseases. The Company intends to
develop and bring to market novel therapeutics that treat diseases
modulated by the immune system, including cancer, autoimmune diseases
and transplant rejection.
The Company's technologies are based on an understanding of the
function of a protein "pump" within cells that is
essential in the processing of tumor antigens, known as Transporters
associated with Antigen Processing ("TAP").
The GeneMax core focus is on commercialization of the TAP technology
as the basis for cancer vaccines. GeneMax holds the worldwide
license to the patented TAP technologies that were discovered
and developed by GeneMax's Chairman and Chief Science Officer,
Dr. Wilfred Jefferies and his team of researchers at the University
of British Columbia Biomedical Research Center.
To view a printable GeneMax Profile in Adobe PDF format, click
here.
To download a free copy of Adobe Acrobat Reader, click
here.
| A lot of medical insiders are excited about GeneMax
coming of age. The company received national media
coverage on the ABC News television program "Business
Now" on June 16, 2003. (If you would like to view the
broadcast, simply go to the GeneMax online homepage by clicking
here. The broadcast is available with a click
of your mouse.) And speaking of mice (of a different form)
in animal trials 70% of mice treated with the Tap
Vaccine remained tumor free, while 100% of the untreated
mice died of multiple tumors within 50 days!
There is a lot more testing to be done, but early results
seem to point to a product that could be amazingly effective. |
|
GMXX
SELECTED FINANCIAL HIGHLIGHTS |
|
Fiscal Year End: 12-31
Industry: Drugs
Transfer Agent: Global Stock Transfer
52- Week High-Low: $20.40 - $1.32
Recent Price: $1.40 |
Daily Volume (3-month avg): 65.0K
Authorized: 25,000,000
Outstanding: 16,813,519
Market Capitalization: $24.5M
Float: 2.1M |
For a current stock quote on GMXX, click
here.
For GMXX SEC filings, click
here.
|
CONTACT |
|
GeneMax Corporation (OTCBB: GMXX) (Frankfurt and
Berlin Exchanges: GX1)
Toll Free Investor Communications: 866.872.0077
Local Phone: 360.332.7734
To View a PowerPoint Investor Presentation at
the GeneMax Web site, click
here.
Want
to feature YOUR company to over 1 MILLION investors?
Click
here to
learn more about our programs or email us directly at info@stockupticks.com
Stockupticks
Safe Harbor Statement: Statements contained in this document,
including those pertaining to estimates and related plans, potential
mergers and acquisitions, estimates, growth, establishing new markets,
expansion into new markets and related plans other than statements
of historical fact, are forward-looking statements subject to a
number of uncertainties that could cause actual results to differ
materially from statements made. StockUpTicks.com is a property
of Market Pathways Financial Relations Incorporated (MP).
MP provides no assurance as to the subject company's plans or ability
to effect any planned and/or proposed actions. MP has no first-hand
knowledge of management and therefore cannot comment on its capabilities,
intent, resources, nor experience and makes no attempt to do so.
Statistical information, dollar amounts, and market size data was
provided by the subject company and related sources believed by
MP to be reliable, but MP provides no assurance, and none is given,
as to the accuracy and completeness of this information.
Disclaimer:
StockUpTicks.com is a property of Market Pathways Financial Relations
Incorporated (MP). The information, opinions and analysis
contained herein are based on sources believed to be reliable
but no representation, expressed or implied, is made as to its
accuracy, completeness or correctness. Past performance
is no guarantee of future results. This report is a paid advertisement
and is for information purposes only and should not be used as
the basis for any investment decision. MP
has been paid $15,000 by Investor Communications Inc. for preparation
and distribution of this report and other advertising services.
This constitutes a conflict of interest as to MP’s ability
to remain objective in its communication regarding the subject
company. Write or call MP for detailed disclosure as required
by Rule 17b of the Securities Act of 1933/1934. MP is not
an investment advisor and this report is not investment advice.
This information is neither a solicitation to buy nor an offer
to sell securities but is a paid advertisement. Information
contained herein contains forward-looking statements and is subject
to significant risks and uncertainties, which will affect the
results. The opinions contained herein reflect our current
judgment and are subject to change without notice. MP and/or its
affiliates, associates and employees from time to time may have
either a long or short position in securities mentioned.
Information contained herein may not be reproduced in whole or
in part without the express written consent of Market Pathways
Financial Relations Incorporated.
|
|
